Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura

Eitemau Tebyg

• Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura
  gan: Zheng, X. Long, et al.
  Cyhoeddwyd: (2010)
• Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura()
  gan: Thomas, Mari R., et al.
  Cyhoeddwyd: (2015)
• Modifying ADAMTS13 to modulate binding of pathogenic autoantibodies of patients with acquired thrombotic thrombocytopenic purpura
  gan: Graça, Nuno A. G., et al.
  Cyhoeddwyd: (2019)
• ADAMTS13 Autoantibodies Cloned from Patients with Acquired Thrombotic Thrombocytopenic Purpura: 2. Pathogenicity in an animal model
  gan: Ostertag, Eric M., et al.
  Cyhoeddwyd: (2016)
• Platelet-delivered ADAMTS13 inhibits arterial thrombosis and prevents thrombotic thrombocytopenic purpura in murine models
  gan: Pickens, Brandy, et al.
  Cyhoeddwyd: (2015)